Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
A phase 1/2 trial of Fludarabine and Cyclophosphamide in advanced solid tumours, run by Beijing Biotech, now recruiting.
Overview
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07523529 by Beijing Biotech, with 72 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine and Cyclophosphamide.
Similar pages
not linked directly; found by shared links- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialStudy of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Shares Cyclophosphamide, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
Shares Fludarabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTarget-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialClinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialSafety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
- TrialA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Shares Fludarabine, Cyclophosphamide and the tag pipeline.